Top Markets
#1 Akedo Akedo +63.85%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.67%
#4 Cross Cross +44.24%
#5 Black Phoenix Black Phoenix +34.14%
#6 Velvet Velvet +29.70%
#7 OVERTAKE OVERTAKE +26.36%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.57%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.55%
#10 Palladium Network Palladium Network +12.47%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Molecular Pharmacology (USA), Ltd. Molecular Pharmacology (USA), Ltd.

Molecular Pharmacology (USA), Ltd.

MLPH
Rank in Stocks #39109
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is... As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.
Share Price
$0.0322
Last synced: 2026-08-12
Market Cap
$643.71K
Change (1 day)
0.00%
Change (1 year)
544.00%
Country
AU
Trade Molecular Pharmacology (USA), Ltd. (MLPH)

Category

Healthcare
Operating Margin for Molecular Pharmacology (USA), Ltd. (MLPH)
Operating Margin as of 2026 TTM: 0.00%
According to Molecular Pharmacology (USA), Ltd. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Molecular Pharmacology (USA), Ltd. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.